{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:06:04Z","timestamp":1793462764538,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AL amyloidosis (light chain; previously also called primary amyloidosis) is a systemic disease characterized by an amyloid deposition process affecting many organs, and which still has unsatisfactory survival of patients. The monoclonal light chains kappa (\u03ba) or lambda (\u03bb) or their fragments form the fibrils that deposit and accumulate in different tissues. Renal involvement is very frequent in AL amyloidosis and can lead to the development of nephrotic syndrome followed by renal failure in some cases. AL amyloidosis ultimately leads to destruction of tissues and progressive disease. With recent advances in the treatment, the importance of an early diagnosis of amyloidosis and correct assessment of its type is high. Histologic confirmation is based on Congo red detection of amyloid deposits in tissues but AL amyloidosis must also be distinguished from other systemic forms of amyloidoses with renal involvement, such as AA amyloidosis, amyloidosis with heavy chain deposition, fibrinogen A\u03b1 or ALECT2 (leukocyte chemotactic factor 2) deposition. Immunofluorescence (IF) plays a key role here. IF on formalin-fixed paraffin-embedded tissue after protease digestion, immunohistochemistry or laser microdissection with mass spectrometry should complete the diagnosis in unclear cases. Standard treatment with melphalan and prednisolone or with cyclophosphamide and dexamethasone has been replaced with newer drugs used for the treatment of multiple myeloma\u2014bortezomib, carfilzomib and ixazomib or thalidomide, lenalidomide and pomalidomide. High-dose melphalan supported by autologous stem cell transplantation remains the therapeutic option for patients with low-risk status. These new treatment options prolong survival from months to years and improve the prognosis in a majority of patients.<\/jats:p>","DOI":"10.1093\/ndt\/gfy291","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T11:11:44Z","timestamp":1536405104000},"page":"1460-1466","source":"Crossref","is-referenced-by-count":93,"title":["AL amyloidosis: advances in diagnostics and treatment"],"prefix":"10.1093","volume":"34","author":[{"given":"Romana","family":"Ry\u0161av\u00e1","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"2020070205540272100_gfy291-B1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"key":"2020070205540272100_gfy291-B2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis (AL) in Olmsted Country, Minnesota: 1950-1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B3","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B4","first-page":"11","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici","year":"2005","journal-title":"Biochem Biophys Acta"},{"key":"2020070205540272100_gfy291-B5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.2015.1093936","article-title":"Novel strategies for the diagnosis and treatment of cardiac amyloidosis","volume":"13","author":"Palladini","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2020070205540272100_gfy291-B6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0272-6386(95)90647-9","article-title":"Treatment of amyloidosis","volume":"26","author":"Tan","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2020070205540272100_gfy291-B7","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","article-title":"Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis, and its utility in clinical practice","volume":"54","author":"Van Gameren","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020070205540272100_gfy291-B8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/134.4.545","article-title":"Amyloidosis\u2014where are we now and where are we heading?","volume":"134","author":"Picken","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2020070205540272100_gfy291-B9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlation of 474 recenet cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205540272100_gfy291-B10","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.ki.5001990","article-title":"Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies","volume":"70","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"key":"2020070205540272100_gfy291-B11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00041552-200211000-00013","article-title":"Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis","volume":"11","author":"Hawkins","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020070205540272100_gfy291-B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2014.333","article-title":"The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease","volume":"87","author":"Yadav","year":"2015","journal-title":"Kidney Int"},{"key":"2020070205540272100_gfy291-B13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"key":"2020070205540272100_gfy291-B14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1515\/CCLM.2011.624","article-title":"N Latex FLC - new monoclonal highperformance assays for the determination of free light chain kappa and lambda","volume":"49","author":"Te Velthuis","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"2020070205540272100_gfy291-B15","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1515\/cclm-2013-0361","article-title":"Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis","volume":"51","author":"Mollee","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"2020070205540272100_gfy291-B16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1515\/cclm-2016-1024","article-title":"Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays","volume":"55","author":"Palladini","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"2020070205540272100_gfy291-B17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneph.2009.151","article-title":"Serum free light chain assessment in monoclonal gammopathy and kidney disease","volume":"5","author":"Hutchison","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2020070205540272100_gfy291-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2013.01.014","article-title":"Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine","volume":"391","author":"Campbell","year":"2013","journal-title":"J Immunol Methods"},{"key":"2020070205540272100_gfy291-B19","doi-asserted-by":"crossref","first-page":"e38061","DOI":"10.1371\/journal.pone.0038061","article-title":"Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (AL)","volume":"7","author":"Ramirez-Alvarado","year":"2012","journal-title":"PLoS One"},{"key":"2020070205540272100_gfy291-B20","first-page":"715","article-title":"Therapy and management of systemic AL (primary) amyloidosis","volume":"136","author":"Palladini","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"2020070205540272100_gfy291-B21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"key":"2020070205540272100_gfy291-B22","first-page":"e40","article-title":"Growth differentiation factor 15 is a new biomarker for survival and renal outcomes in light chain (AL) amyloidosis","volume":"17","author":"Kastritis","year":"2017","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2020070205540272100_gfy291-B24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjh.12191","article-title":"Light chain amyloidosis 2012: a new era","volume":"160","author":"Gatt","year":"2013","journal-title":"Br J Haematol"},{"key":"2020070205540272100_gfy291-B25","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020070205540272100_gfy291-B26","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2020070205540272100_gfy291-B27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020070205540272100_gfy291-B28","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3324\/haematol.2012.079210","article-title":"A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?","volume":"98","author":"Leung","year":"2013","journal-title":"Hematologica"},{"key":"2020070205540272100_gfy291-B29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000444206","article-title":"The prevalence and management of systemic amyloidosis in western countries","volume":"2","author":"Nienhuis","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"2020070205540272100_gfy291-B30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"2020070205540272100_gfy291-B31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428199709059690","article-title":"Treatment of AL-amyloidosis with dexamethasone plus alpha interferon","volume":"27","author":"Dhodapkar","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"2020070205540272100_gfy291-B32","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethazone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B33","first-page":"81","article-title":"Oral melphalan and dexamethasone for AL amyloidosis: efficacy, prognostic factors and response criteria","volume":"17","author":"Palladini","year":"2010","journal-title":"Amyloid"},{"key":"2020070205540272100_gfy291-B34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/10428194.2011.622422","article-title":"Efficacy of bendamustine in relapsed\/refractory myeloma patients: results from the French compassionate use program","volume":"53","author":"Damaj","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2020070205540272100_gfy291-B35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"key":"2020070205540272100_gfy291-B36","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B37","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B38","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1038\/bcj.2017.47","article-title":"Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib","volume":"7","author":"Kastritis","year":"2017","journal-title":"Blood Cancer J"},{"key":"2020070205540272100_gfy291-B39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"key":"2020070205540272100_gfy291-B40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205540272100_gfy291-B41","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B42","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"2020070205540272100_gfy291-B44","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205540272100_gfy291-B45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V86.3.855.855","article-title":"New drug therapy of amyloidoses: resorption of AL-type deposits with 4\u00b4-iodo- 4\u00b4-deoxydoxorubicin","volume":"86","author":"Gianni","year":"1995","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"2020070205540272100_gfy291-B47","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"2020070205540272100_gfy291-B48","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"2020070205540272100_gfy291-B49","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020070205540272100_gfy291-B50","first-page":"770","article-title":"Systemic amyloidosis: novel therapies and role of biomarkers","volume":"32","author":"Nuvolone","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/9\/1460\/33456020\/gfy291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/9\/1460\/33456020\/gfy291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T23:44:31Z","timestamp":1661989471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/9\/1460\/5123556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,10,8]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy291","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2018,10,8]]}}}